The Multidisciplinary Association for Psychedelic Studies (MAPS) founder and executive director, Rick Doblin, said in an interview with Fox Business Live that the FDA would approve MDMA-assisted therapy for PTSD in April or May of 2024.
Last year, MAPS announced the completion of the MAPP2 Phase 3 study, which is the organization’s second to use MDMA (3,4-methylenedioxymethamphetamine) therapy for PTSD treatment. The organization anticipates releasing data from the study in the first quarter of 2023.
In the Fox interview, Doblin said that the MAPP2 study achieved confirmatory results for treating PTSD.
Doblin underscored the importance of therapy in the Phase 3 trial. “It’s the therapy that is the primary active treatment, and the MDMA, the medicine, makes the therapy more effective,” he said in the interview.
He also noted that the Veterans Administration pays billions of dollars annually for disability, including for veterans with PTSD. Accordin…